CK Life Sciences International (Holdings), Inc. (00775.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 0.55

From 52W high−46.60%

Volume782000.00

Market capHKD 5.35B

P/E (TTM)—

P/S (TTM)1.0x

Div yield—

Key dataSep 18, 2026

Open

HKD 0.55

From 52W high

−46.60%

Volume

782000.00

Market cap

HKD 5.35B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

154.5x

P/E (TTM)

—

RSI (14)

43.0

MomentumView details →

1D Return

+0.92%

YTD Return

−32.93%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

154.5x

EV/Sales

2.1x

P/S (TTM)

1.0x

P/B (TTM)

1.4x

ProfitabilityView details →

Gross Margin

13.39%

Net Margin

−1.20%

EBITDA Margin

1.38%

ROE (TTM)

−1.68%

ROA (TTM)

−0.55%

Asset Turnover

0.46x

GrowthView details →

Revenue YoY

+0.50%

EPS YoY

+76.90%

FCF YoY

—

Revenue CAGR 3Y

+0.84%

EPS CAGR 3Y

−46.97%

EBITDA YoY

+712.22%

MomentumView details →

1D Return

+0.92%

YTD Return

−32.93%

1Y Return

−42.11%

RSI (14)

43.0

vs 50D SMA

−3.95%

vs 200D SMA

−23.02%

Capital & dividendView details →

Debt/Equity

1.73x

Current Ratio

0.91x

Quick Ratio

0.51x

Div Yield

—

Div Rate

—

Div Growth 1Y

−20.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

11.01B

Net Income (TTM)

−344.73M

Op. CF (TTM)

125.36M

Latest newsMore news →

CK Life Sciences International reported interim results for the six months ended June 2026, with revenue of HK$2.716 billion, up 4.2% year-on-year, and a narrowed net loss of HK$28.73 million, compared with a loss of HK$151 million in the same period last year.40d ago

Similar companies

Dianthus Therapeutics, Inc.DNTH Apellis Pharmaceuticals, Inc.APLS 博拓生物688767.SH PTC Therapeutics, Inc.PTCT Cogent Biosciences, Inc.COGT CRISPR Therapeutics AGCRSP Find similar companies →

Latest newsMore news →

CK Life Sciences International reported interim results for the six months ended June 2026, with revenue of HK$2.716 billion, up 4.2% year-on-year, and a narrowed net loss of HK$28.73 million, compared with a loss of HK$151 million in the same period last year.40d ago